Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer

Robert W. Veltri, M. Craig Miller, Gang Zhao, Angela Ng, Garry M. Marley, George L. Wright, Robert L. Vessella, David Ralph

Research output: Contribution to journalArticle

Abstract

Objectives. Using arbitrarily primed polymerase chain reaction (AP-PCR) ribonucleic acid (RNA) fingerprinting, we discovered a messenger RNA (mRNA) that encoded the cytokine interleukin-8 (IL-8) that was up-regulated in the peripheral blood leukocytes (PBLs) of patients with metastatic prostate cancer (CAP) compared with similar cells from healthy individuals. We compared the total prostate-specific antigen (PSA) levels, the free/total (f/t) PSA ratios, and the immunoreactive IL-8 serum concentrations in patients with either biopsy-confirmed benign prostatic hyperplasia (BPH) or CaP. Methods. The sera from 35 apparently healthy normal volunteers and 146 patients with biopsy-confirmed BPH and CaP obtained from two academic centers were retrospectively examined to determine the serum levels of IL-8, total PSA (tPSA), and the f/t PSA ratio. Logistic regression and trend analysis statistical methods were used to assess the results. Results. Normals (n = 35), BPH patients (n = 53), patients with clinical Stages A to C CaP (n = 81), and patients with metastatic CaP (n = 12) had mean levels of IL-8 of 6.8, 6.5, 15.6, and 27.8 pg/mL, respectively. The IL-8 serum concentrations correlated with increasing CaP stage and also differentiated BPH from clinical Stages A, B, C, or D CaP better than tPSA and performed similarly to the f/t PSA ratio. The combination of the IL-8 levels and f/t PSA ratios using multivariate logistic regression analysis distinguished BPH from Stages A, B, C, or D CaP or only Stages A and B with a receiver operating characteristic area under the curve of 89.8% and 87.5%, respectively (P

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalUrology
Volume53
Issue number1
DOIs
StatePublished - Jan 1999
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Prostate-Specific Antigen
Interleukin-8
Prostatic Neoplasms
Serum
Healthy Volunteers
Logistic Models
Regression Analysis
RNA
Biopsy
ROC Curve
Area Under Curve
Leukocytes
Cytokines
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Urology

Cite this

Veltri, R. W., Miller, M. C., Zhao, G., Ng, A., Marley, G. M., Wright, G. L., ... Ralph, D. (1999). Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology, 53(1), 139-147. https://doi.org/10.1016/S0090-4295(98)00455-5

Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. / Veltri, Robert W.; Miller, M. Craig; Zhao, Gang; Ng, Angela; Marley, Garry M.; Wright, George L.; Vessella, Robert L.; Ralph, David.

In: Urology, Vol. 53, No. 1, 01.1999, p. 139-147.

Research output: Contribution to journalArticle

Veltri, RW, Miller, MC, Zhao, G, Ng, A, Marley, GM, Wright, GL, Vessella, RL & Ralph, D 1999, 'Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer', Urology, vol. 53, no. 1, pp. 139-147. https://doi.org/10.1016/S0090-4295(98)00455-5
Veltri, Robert W. ; Miller, M. Craig ; Zhao, Gang ; Ng, Angela ; Marley, Garry M. ; Wright, George L. ; Vessella, Robert L. ; Ralph, David. / Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. In: Urology. 1999 ; Vol. 53, No. 1. pp. 139-147.
@article{0bc4977b881843089f0008ecd3c665e7,
title = "Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer",
abstract = "Objectives. Using arbitrarily primed polymerase chain reaction (AP-PCR) ribonucleic acid (RNA) fingerprinting, we discovered a messenger RNA (mRNA) that encoded the cytokine interleukin-8 (IL-8) that was up-regulated in the peripheral blood leukocytes (PBLs) of patients with metastatic prostate cancer (CAP) compared with similar cells from healthy individuals. We compared the total prostate-specific antigen (PSA) levels, the free/total (f/t) PSA ratios, and the immunoreactive IL-8 serum concentrations in patients with either biopsy-confirmed benign prostatic hyperplasia (BPH) or CaP. Methods. The sera from 35 apparently healthy normal volunteers and 146 patients with biopsy-confirmed BPH and CaP obtained from two academic centers were retrospectively examined to determine the serum levels of IL-8, total PSA (tPSA), and the f/t PSA ratio. Logistic regression and trend analysis statistical methods were used to assess the results. Results. Normals (n = 35), BPH patients (n = 53), patients with clinical Stages A to C CaP (n = 81), and patients with metastatic CaP (n = 12) had mean levels of IL-8 of 6.8, 6.5, 15.6, and 27.8 pg/mL, respectively. The IL-8 serum concentrations correlated with increasing CaP stage and also differentiated BPH from clinical Stages A, B, C, or D CaP better than tPSA and performed similarly to the f/t PSA ratio. The combination of the IL-8 levels and f/t PSA ratios using multivariate logistic regression analysis distinguished BPH from Stages A, B, C, or D CaP or only Stages A and B with a receiver operating characteristic area under the curve of 89.8{\%} and 87.5{\%}, respectively (P",
author = "Veltri, {Robert W.} and Miller, {M. Craig} and Gang Zhao and Angela Ng and Marley, {Garry M.} and Wright, {George L.} and Vessella, {Robert L.} and David Ralph",
year = "1999",
month = "1",
doi = "10.1016/S0090-4295(98)00455-5",
language = "English (US)",
volume = "53",
pages = "139--147",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer

AU - Veltri, Robert W.

AU - Miller, M. Craig

AU - Zhao, Gang

AU - Ng, Angela

AU - Marley, Garry M.

AU - Wright, George L.

AU - Vessella, Robert L.

AU - Ralph, David

PY - 1999/1

Y1 - 1999/1

N2 - Objectives. Using arbitrarily primed polymerase chain reaction (AP-PCR) ribonucleic acid (RNA) fingerprinting, we discovered a messenger RNA (mRNA) that encoded the cytokine interleukin-8 (IL-8) that was up-regulated in the peripheral blood leukocytes (PBLs) of patients with metastatic prostate cancer (CAP) compared with similar cells from healthy individuals. We compared the total prostate-specific antigen (PSA) levels, the free/total (f/t) PSA ratios, and the immunoreactive IL-8 serum concentrations in patients with either biopsy-confirmed benign prostatic hyperplasia (BPH) or CaP. Methods. The sera from 35 apparently healthy normal volunteers and 146 patients with biopsy-confirmed BPH and CaP obtained from two academic centers were retrospectively examined to determine the serum levels of IL-8, total PSA (tPSA), and the f/t PSA ratio. Logistic regression and trend analysis statistical methods were used to assess the results. Results. Normals (n = 35), BPH patients (n = 53), patients with clinical Stages A to C CaP (n = 81), and patients with metastatic CaP (n = 12) had mean levels of IL-8 of 6.8, 6.5, 15.6, and 27.8 pg/mL, respectively. The IL-8 serum concentrations correlated with increasing CaP stage and also differentiated BPH from clinical Stages A, B, C, or D CaP better than tPSA and performed similarly to the f/t PSA ratio. The combination of the IL-8 levels and f/t PSA ratios using multivariate logistic regression analysis distinguished BPH from Stages A, B, C, or D CaP or only Stages A and B with a receiver operating characteristic area under the curve of 89.8% and 87.5%, respectively (P

AB - Objectives. Using arbitrarily primed polymerase chain reaction (AP-PCR) ribonucleic acid (RNA) fingerprinting, we discovered a messenger RNA (mRNA) that encoded the cytokine interleukin-8 (IL-8) that was up-regulated in the peripheral blood leukocytes (PBLs) of patients with metastatic prostate cancer (CAP) compared with similar cells from healthy individuals. We compared the total prostate-specific antigen (PSA) levels, the free/total (f/t) PSA ratios, and the immunoreactive IL-8 serum concentrations in patients with either biopsy-confirmed benign prostatic hyperplasia (BPH) or CaP. Methods. The sera from 35 apparently healthy normal volunteers and 146 patients with biopsy-confirmed BPH and CaP obtained from two academic centers were retrospectively examined to determine the serum levels of IL-8, total PSA (tPSA), and the f/t PSA ratio. Logistic regression and trend analysis statistical methods were used to assess the results. Results. Normals (n = 35), BPH patients (n = 53), patients with clinical Stages A to C CaP (n = 81), and patients with metastatic CaP (n = 12) had mean levels of IL-8 of 6.8, 6.5, 15.6, and 27.8 pg/mL, respectively. The IL-8 serum concentrations correlated with increasing CaP stage and also differentiated BPH from clinical Stages A, B, C, or D CaP better than tPSA and performed similarly to the f/t PSA ratio. The combination of the IL-8 levels and f/t PSA ratios using multivariate logistic regression analysis distinguished BPH from Stages A, B, C, or D CaP or only Stages A and B with a receiver operating characteristic area under the curve of 89.8% and 87.5%, respectively (P

UR - http://www.scopus.com/inward/record.url?scp=0032937653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032937653&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(98)00455-5

DO - 10.1016/S0090-4295(98)00455-5

M3 - Article

C2 - 9886603

AN - SCOPUS:0032937653

VL - 53

SP - 139

EP - 147

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -